Most deliverable DES1, featuring Core Wire Technology
Broad size matrix to optimise treatment of complex clinical scenarios
Proven long-term safety and efficacy shown in the Global RESOLUTE Program
1Based on bench test data vs. Promus Premier™ DES, Synergy™ II DES, Xience Xpedition™ DES and Resolute Integrity™ DES.
Through an innovative Medtronic-developed process, Resolute Onyx™ DES is manufactured from a single strand of core wire into a sinusoidal wave form that provides a fluid range of motion
Resolute Onyx DES builds on the Integrity™ platform’s acute procedural success2 for even greater deliverability
Core Wire Technology enables thinner struts with increased radiopacity and no compromise to radial or longitudinal strength
A new 2.00-mm diameter with longer stent lengths expands treatment options for patients with diabetes and diffuse disease
|Diameter (mm)||Stent Length (mm)|
|Shaded cells highlight modifications to the size matrix: 2.00-mm stents and 34- and 38-mm lengths expand the size matrix; an 8-mm length replaces the 9-mm Resolute Integrity™ length; and a 15-mm length replaces the 14-mm Resolute Integrity length.
2.00–2.50-mm stents can be expanded to 3.25 mm; 2.75–3.00-mm stents can be expanded to 3.75 mm; 3.50–4.00-mm stents can be expanded to 4.75 mm.
RESOLUTE All Comers showed overall excellent long-term performance at five years:
Low TLF: Resolute™ ZES 17.1% vs. Xience™ EES 16.3% (p = 0.65)
No increased risk for stent thrombosis with interruption or discontinuation of DAPT after one month1
Bhatt. Relation of stent thrombosis to interruption of dual antiplatelet therapy after Resolute zotarolimus-eluting stent Implantation. TCT 2013. Kandzari. Pharmacodynamic considerations and clinical Impact of dual antiplatelet therapy interruption after Resolute zotarolimus-eluting stent implantation. ACC 2014.
Post-hoc RESOLUTE Pooled DAPT analysis was not powered for the analysis shown.
* Including patients with no DAPT interruption except for ST while on DAPT through 12 months.
† Three-day cutoff selected because studies have shown that discontinuation of at least three days is necessary for platelet function recovery in most individuals.
‡ Patient with a history of thrombosis was on DAPT at the time of ST event but had interrupted DAPT for two consecutive days prior to the event.
§ Kirtane. Long-term impact of antiplatelet therapy interruption on ST following PCI with the Resolute zotarolimus-eluting stent. TCT 2013.
ESC guidelines recommend DAPT duration of 6–12 months after DES implantation in all patients and one year after ACS, irrespective of the type of implanted stent.
Sustained safety of 1.2% ST through five years in more than 7500 patients from the RESOLUTE Pooled analysis
“One year data from the RESOLUTE Clinical Program indicates low stent thrombosis rates for those that interrupted or discontinued DAPT any time after one month. While physicians should adhere to current ESC or ACC/AHA/SCAI guidelines for PCI, patients who interrupt or discontinue DAPT medication one month or more after stent implantation are considered at low risk and showed no increased risk for stent thrombosis.”
Medtronic has added this significant statement of finding to our labelingin order to provide important information to implanting physicians.
This website contains information regarding CE Marked products with limited release in other geographies. These products may not be available in your geography. This website is not intended to be viewed by residents of the United States, Japan or France.